EUCTR2020-001891-14-ESActive, not recruitingPhase 1
Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2
Fundación Neumosur0 sites140 target enrollmentStarted: May 5, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 140
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Patients over 18 years old
- •2. Signature of informed consent
- •3. Diagnosis by positive PCR for SARS-CoV2 infection
- •4. They require hospital admission due to fever and other of the established CoV2 admission criteria.
- •5. Patients with a weight greater than or equal to 60 Kg.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
Exclusion Criteria
- •1. Allergy to LMWH.
- •2. Contraindication for anticoagulation (platelets <25 x 10E9 / L or severe active bleeding, major or clinically relevant bleeding)
- •3. Pregnancy.
- •4. Patients with extreme weights. BMI greater than 40.
- •5. Need for chronic anticoagulant treatment.
- •6. Need for treatment with high-flow oxygen therapy or mechanical ventilation at the time of study recruitment (within the first 24 hours after admission).
- •7. Participation in another disease treatment trial
- •venous thromboembolic.
Investigators
Similar Trials
Completed
Not Applicable
Effectiveness of low-molecular-weight heparin for prevention of deep venous thrombosis after surgery for colorectal cancer in Japanese patients: a randomized controlled phase III trialcolorectal cancerJPRN-UMIN000030582Tokyo Metropolitan Hiroo Hospital160
Active, not recruiting
Phase 1
ow-molecular-weight heparin to prevent venous thromboembolism in COVID-19 patients : a randomized controlled trial of different dosesPrevention of thromboembolic events in hospitalised COVID-19 infected patientsMedDRA version: 20.0Level: HLGTClassification code 10014523Term: Embolism and thrombosisSystem Organ Class: 10047065 - Vascular disordersEUCTR2020-001709-21-FRCHRU de Nancy550
Not yet recruiting
Phase 4
A study to determine effectiveness of Low Molecular Weight Heparin in reduction ofseverity of Acute PancreatitisCTRI/2022/12/048036Jawaharlal Institute of Postgraduate Medical Education and Research
Completed
Phase 4
Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two dosespulmonary embolismNL-OMON55412Academisch Medisch Centrum200
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womeEUCTR2012-001505-24-IEThe Rotunda Maternity Hospital850